Stocktoria
Alpha Teknova, Inc. TKNO
Alpha Teknova, Inc. (TKNO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $40.5M at a -42.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.05 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.26 |
| Retained earnings / assets | -1.311 |
| EBIT / assets | -0.164 |
| Equity / liabilities | 1.976 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| NTLA | Intellia Therapeutics, Inc. | 2/9 | -6.12 | — | +16.9% |
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
| BMRA | BIOMERICA INC | 2/9 | — | — | — |
| IMDX | Insight Molecular Diagnostics Inc. | 3/9 | — | — | — |
| CLDX | Celldex Therapeutics, Inc. | 1/9 | 1.9 | — | — |
About Alpha Teknova, Inc.
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
FAQ
Is TKNO financially healthy?
Alpha Teknova, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TKNO pay a dividend?
No, Alpha Teknova, Inc. does not currently pay a dividend.
How profitable is TKNO?
In FY2025, Alpha Teknova, Inc. had a net margin of -42.6% and a return on equity of -25.1%.
What is the analyst price target for TKNO?
The average Wall-Street price target for Alpha Teknova, Inc. is $9.00, about 21.8% above the recent price, from 3 analysts.
Is TKNO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Alpha Teknova, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.